Skye Bioscience (SKYE) Gross Profit (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly Gross Profit of $105258.0 for Q2 2014, up 20.53% year-over-year from $87328.0 in Q2 2013, and up 59.41% quarter-over-quarter from $66029.0 in Q4 2013.
Skye Bioscience (SKYE) Gross Profit (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported Gross Profit for 2 consecutive years, with $105258.0 the latest figure, recorded in Q2 2014.
- In Q2 2014, Gross Profit rose 20.53% year-over-year to $105258.0; the TTM figure through Apr 2014 stood at $330690.0 (changed N/A YoY), while the FY2013 annual figure was $272628.0, up 1620.38% from the prior year.
- Gross Profit advanced to $105258.0 in Q2 2014 per SKYE's latest filing, from $66029.0 in the prior quarter.
- Across five years, Gross Profit topped out at $105258.0 in Q2 2014 and bottomed at $47310.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | 105,258.00 |
| Apr 30, 2014 | 105,258.00 |
| Oct 31, 2013 | 66,029.00 |
| Oct 31, 2013 | 66,029.00 |
| Jul 31, 2013 | 72,075.00 |
| Jul 31, 2013 | 72,075.00 |
| Apr 30, 2013 | 87,328.00 |
| Apr 30, 2013 | 87,328.00 |
| Jan 31, 2013 | 47,310.00 |
| Jan 31, 2013 | 47,310.00 |